Dextromethorphan

• CAT Number: I006465
• CAS Number: 125-71-3 (free base)
• Molecular Formula: C18H25NO
• Molecular Weight: 271.4
• Purity: ≥95%
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• InChI: InChI=1S/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17-,18-/m0/s1
• InChIKey: MKXZASYAUGDDCJ-SZMVWBNQSA-N
• SMILES: CN1CCC23CCCCC2C1CC4=C3C=C(C=C4)OC

Dextromethorphan (Cat. No.:I006465) is a morphine-like cough suppressant with sedative and dissociative properties. It acts primarily by inhibiting the cough center of the medulla oblongata. The primary use of dextromethorphan is as a cough suppressant for the temporary relief of coughs caused by minor throat and bronchial irritations (such as those usually accompanying influenza and the common cold), and those caused by inhaled particulate irritants.

Reference

1:Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. Murrough JW, Wade E, Sayed S, Ahle G, Kiraly DD, Welch A, Collins KA, Soleimani L, Iosifescu DV, Charney DS.J Affect Disord. 2017 Apr 29;218:277-283. doi: 10.1016/j.jad.2017.04.072. [Epub ahead of print] PMID: 28478356 2:Interaction of dextromethorphan hydrobromide with DNA: multispectral, voltammetric, and molecular docking technology. Bi S, Zhou H, Wu J, Wang Y.J Biomol Struct Dyn. 2017 Apr 16:1-7. doi: 10.1080/07391102.2017.1313781. [Epub ahead of print] No abstract available. PMID: 28413907 3:Dextromethorphan and Methylxanthines Might Be Useful in the Treatment of Methotrexate-Induced Neurotoxicity. Fernández-Fernández FJ, Ameneiros-Lago E, Lijó-Carballeda C, Sesma P.Pediatr Emerg Care. 2017 May;33(5):380. doi: 10.1097/PEC.0000000000001128. No abstract available. PMID: 28376072 4:Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson/’s disease. Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.Mov Disord. 2017 Mar 30. doi: 10.1002/mds.26976. [Epub ahead of print] PMID: 28370447 5:In vivo characterization of CYP2D6*12, *29 and *84 using dextromethorphan as a probe drug: a case report. Gaedigk A, Twist GP, Farrow EG, Lowry JA, Soden SE, Miller NA.Pharmacogenomics. 2017 Apr;18(5):427-431. doi: 10.2217/pgs-2016-0192. Epub 2017 Mar 14. PMID: 28290770 Free Article6:Dextromethorphan upregulates osteoblast and osteoclast activity but does not attenuate ovariectomy-induced osteoporosis. Wu JL, Tsai WY, Chen JH, Wong CS.Life Sci. 2017 Mar 15;173:145-149. doi: 10.1016/j.lfs.2017.01.011. Epub 2017 Jan 30. PMID: 28153746 7:Reversible and Selective Encapsulation of Dextromethorphan and β-Estradiol Using an Asymmetric Molecular Capsule Assembled via the Weak-Link Approach. Mendez-Arroyo J, d/’Aquino AI, Chinen AB, Manraj YD, Mirkin CA.J Am Chem Soc. 2017 Feb 1;139(4):1368-1371. doi: 10.1021/jacs.6b10027. Epub 2017 Jan 17. PMID: 28094924 8:Consequences of daily corticosteroid dosing with or without pre-treatment with quinidine on the in vivo cytochrome P450 2D (CYP2D) enzyme in rats: effect on O-demethylation activity of dextromethorphan and expression levels of CYP2D1 mRNA. Giri P, Delvadia P, Gupta L, Patel N, Trivedi P, Lad K, Patel HM, Srinivas NR.Xenobiotica. 2017 Jan 19:1-10. doi: 10.1080/00498254.2016.1275064. [Epub ahead of print] PMID: 28010169 9:Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients. Wahler RG Jr, Reiman AT, Schrader JV.J Palliat Med. 2017 Mar;20(3):294-297. doi: 10.1089/jpm.2016.0277. Epub 2016 Dec 20. PMID: 27997281 10:Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT. Ma KH, Liu TT, Weng SJ, Chen CF, Huang YS, Chueh SH, Liao MH, Chang KW, Sung CC, Hsu TH, Huang WS, Cheng CY.Sci Rep. 2016 Dec 12;6:38695. doi: 10.1038/srep38695. PMID: 27941910 Free PMC Article